Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 1.01, 9.01 · 8-K

RAPHAEL PHARMACEUTICAL INC

RAPHOTCEQUITYCurrent

Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On July 30, 2026, Raphael Pharmaceutical Inc. (the “Company”) entered into an Enterprise AI Transformation and Growth Partnership with AIcreatesAI Inc. (“AIcreatesAI”) pursuant to an Annual Managed Services Proposal and Agreement (the “Agreement”). The Agreement became effective on July 30, 2026, the date of the last signature by the parties.…

Filed Sep 1, 2026Accepted Sep 1, 2026, 12:51 PM EDTCIK 1415397Accession 0001213900-26-096113
Share

Company context

Current securities

Recent company filings

  1. 10-Q filingAug 14, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJul 17, 2026
  3. 10-Q filingMay 14, 2026
  4. 10-K filingMar 31, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsMar 24, 2026

Disclosure sections

Items 1.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement. On July 30, 2026, Raphael Pharmaceutical Inc. (the “Company”) entered into an Enterprise AI Transformation and Growth Partnership with AIcreatesAI Inc. (“AIcreatesAI”) pursuant to an Annual Managed Services Proposal and Agreement (the “Agreement”). The Agreement became effective on July 30, 2026, the date of the last signature by the parties. Under the Agreement, AIcreatesAI will serve as the Company’s managed artificial intelligence transformation, commercialization, communications, product and growth operations partner. The initial term is twelve months. The annual managed-services fee is $180,000, payable in monthly installments of $15,000, subject to the deferred-payment provisions described in the Agreement. The services contemplated by the Agreement include, among other matters, digital transformation and operating-system implementation; website, application and CRM development and management; analytics and executive dashboards; approved marketing, content, social-media, email and press support; research and product intelligence; partnership-development support; and investor and corporate communications, in each case subject to the Company’s approval, applicable law and the compliance controls set forth in the Agreement. The Agreement provides that when funds are temporarily unavailable, any unpaid service invoices automatically become deferred payment obligations and remain payable upon the Company’s receipt of financing, capital investment, commercial revenues or other available financial resources. With AIcreatesAI’s written consent, the Company may satisfy deferred payment obligations through the issuance of Company common shares, subject to applicable securities laws and OTC Markets requirements. The Agreement also contemplates the design, development and maintenance of a Company-branded digital token platform, subject to Board approval and applicable law. In consideration for ongoing operation and maintenance of that platform, AIcreatesAI is entitled to receive two percent (2%) of the net profits generated from the platform, separate from the annual service fee. The Agreement does not itself authorize regulated token issuance, exchange listing, custody, securities sales or other regulated financial services. The Agreement may be terminated by either party for a material breach that remains uncured for fifteen days after written notice. The parties are independent contractors, and the Agreement does not create a partnership, joint venture, fiduciary relationship or equity partnership. The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.